Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.
about
Targeted therapy of gastrointestinal stromal tumoursWithdrawal of anticancer therapy in advanced disease: a systematic literature reviewUnveiling changes in the landscape of patient populations in cancer early drug developmentCurrent management and prognostic features for gastrointestinal stromal tumor (GIST)Role of imatinib in the management of early, operable, and advanced GI stromal tumors (GISTs)Key messages from the BFR14 trial of the French Sarcoma Group.Strategies for modern biomarker and drug development in oncology.A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted solid tumoursGastrointestinal stromal tumor.Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial.Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib.Imatinib: a breakthrough of targeted therapy in cancer.Extragastrointestinal stromal tumour of the lesser omentum: A case report and literature review.Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial.Cost Effectiveness of Universal Hepatitis B Virus Screening in Patients Beginning Chemotherapy for Sarcomas or GI Stromal Tumors.Optimizing adherence to adjuvant imatinib in gastrointestinal stromal tumor.Molecular basis and management of gastrointestinal stromal tumorsNCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST).Stromal tumor of the lesser omentum : a case report.Pediatric and wild-type gastrointestinal stromal tumor: new therapeutic approaches.Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors.Is there something other than imatinib mesilate in therapeutic options for GIST?Adjuvant therapy for high-risk gastrointestinal stromal tumour: considerations for optimal management.The role of adjuvant and neoadjuvant therapy in gastrointestinal stromal tumors.Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate.A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis.Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.New fronts in the adjuvant treatment of GIST.Metastasectomy for gastrointestinal stromal tumors.Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelinesRebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay.Imatinib as the first and only treatment in Europe for adult patients at significant risk of relapse following gastrointestinal stromal tumor removal.Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma group.Randomized clinical trials in gastrointestinal stromal tumorsZNF32 inhibits autophagy through the mTOR pathway and protects MCF-7 cells from stimulus-induced cell death.Antitumor effect of the tyrosine kinase inhibitor nilotinib on gastrointestinal stromal tumor (GIST) and imatinib-resistant GIST cells3'-deoxy-3'-[18F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition.
P2860
Q26745633-2F35D281-AB1B-4E11-82A9-43F520714F7DQ26777486-AAE01A36-5696-43BE-83EC-25561C1052CBQ28073826-E067ADE4-7FB8-462D-92D2-95073E88AEDDQ28391684-C645FF8C-A05F-47F4-8AE2-68522132626BQ28765146-7B26B096-5988-410C-8F48-1F0F2583AF5EQ30245384-528801E7-2221-4DCD-8052-21A36BC5A5DDQ30590270-064F2CDC-BD1B-4857-A06E-1D6F2252F058Q33274982-CB554F52-8EA6-4B1B-8922-E5EE8571E147Q33489084-F59B2F69-E816-46F8-A406-2CEF1716ACD6Q33561602-1A7500FF-B453-455E-90B8-D074023D69CEQ33644791-25ED2579-41EE-4A8B-AA15-92DB9D1433D7Q33747261-3B15CC08-886A-4F9E-B5DD-89896137BC08Q33806925-A0F9140D-EB0E-4A06-A037-75F163FF4F43Q33821400-242BF9C9-1F72-4A9D-8B91-6F2064FC362CQ33872813-D26ABDE0-B17F-4666-A54A-AA4F8F861C4CQ33885999-5A4B2CEC-EB4E-4586-B304-384C95885BA2Q33903598-17C5A328-185B-42C5-869C-2F6E50A25553Q33921067-C4CD7D55-696C-4B58-93FD-C5FBC6672A09Q34041573-5DF986CB-325D-4AEA-948D-E3C419CAE8B9Q34069556-B51A4097-14AB-44E1-B1AE-DA3A16B4F208Q34091637-EFC9DBF3-6642-4150-8649-2C44CB00FAFCQ34171517-321EF3B6-85BC-4DF9-A4BA-E245882D0F3CQ34202396-CB220BDA-C9BA-4300-8F5C-B179994349D7Q34207379-1E7003FA-5D5C-4274-AC57-8D70B21F5850Q34300784-4BAC8423-AFAE-489E-A747-C792C3A2200BQ34359712-5BB78E33-EAE4-45E4-9AE5-8C4665034A65Q34596126-6B6BE3C6-C6AD-470E-AD58-E65A105FE739Q34599344-F54685C8-5F82-486B-B453-72D77C3F4F01Q34636081-DDFD9666-C1C8-4992-85CB-C1DF6B71818CQ34655266-3BD42548-8724-4C1A-B6EA-35B1BD6A42A8Q34656880-9B57D52A-AFDD-4313-943F-3940ECDB7CF5Q34662946-841C5DD6-8476-40EE-98A4-7ABDD13BFB03Q34672344-2960B355-8B5B-474E-815A-7F5F36EED761Q34762839-2A971D9F-7352-41E6-A3D5-5D9C6C5C17A0Q35026332-9CEDFF20-F7F7-47F8-A503-1F139BDEFC1FQ35111851-60119BCD-A8D1-4E77-B5E8-81304530093BQ35188114-413B5629-F56A-4F38-B093-DEC6D891AA06Q35193672-287D044B-90C9-416C-8694-E86ACAAEC6B6Q35252470-8F8F476F-5908-41EA-A3D2-9E8C11557E81Q35469515-E16984D7-F4A9-4128-9D5E-4F65F94DCCC2
P2860
Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Prospective multicentric rando ...... ear: the French Sarcoma Group.
@en
Prospective multicentric rando ...... ear: the French Sarcoma Group.
@nl
type
label
Prospective multicentric rando ...... ear: the French Sarcoma Group.
@en
Prospective multicentric rando ...... ear: the French Sarcoma Group.
@nl
prefLabel
Prospective multicentric rando ...... ear: the French Sarcoma Group.
@en
Prospective multicentric rando ...... ear: the French Sarcoma Group.
@nl
P2093
P356
P1476
Prospective multicentric rando ...... ear: the French Sarcoma Group.
@en
P2093
Antoine Adenis
Axel Le Cesne
Catherine Delbaldo
Cecile Guillemet
David Perol
Didier Cupissol
Emmanuelle Bompas
Florence Duffaud
Isabelle Ray-Coquard
P304
P356
10.1200/JCO.2006.09.0183
P407
P577
2007-03-01T00:00:00Z